Skip to content

Krensavage Asset Management, LLC

Follow

13F filer, CIK 1609251, NEW YORK, NY

Krensavage Asset Management, LLC reported $265,382,000 across 20 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-17. Its ten largest share positions make up 88.07% of the portfolio.

Accepted , ingested 13F-HR 0001609251-26-000006

Period
2026-09-30
Reported value
$265M
Holdings
20
Top 10 weight
88.07%
New
3
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
RAREadded+749,988$11.3M
ARDXadded+1,280,969$4.38M
SUPNadded+70,000$3.01M
ANIPnew+13,000$944K
ACADnew+40,000$806K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
EXELreduced-71,300-$4.16M
REGNexited-6,000-$3.74M
UTHRreduced-3,000-$1.63M
EOLSreduced-100,000-$800K

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001609251-26-000006, largest first. % of portfolio is the value over $265,382,000, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
JAZZJAZZ PHARMACEUTICALS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 105,803 shares; 2025Q1: 100,703 shares; 2025Q2: 164,816 shares; 2025Q3: 167,816 shares; 2025Q4: 167,816 shares; 2026Q1: 167,816 shares; 2026Q2: 167,816 shares; 2026Q3: 167,816 shares 167,816$38.9M14.64%0Timeline
ENTAENANTA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 2,117,390 shares; 2025Q1: 2,116,586 shares; 2025Q2: 2,114,444 shares; 2025Q3: 2,114,444 shares; 2025Q4: 2,766,390 shares; 2026Q1: 2,866,138 shares; 2026Q2: 2,866,138 shares; 2026Q3: 2,866,138 shares 2,866,138$37.8M14.23%0Timeline
UTHRUNITED THERAPEUTICS CORP DELQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 92,057 shares; 2025Q1: 98,228 shares; 2025Q2: 101,146 shares; 2025Q3: 97,646 shares; 2025Q4: 91,282 shares; 2026Q1: 84,282 shares; 2026Q2: 69,282 shares; 2026Q3: 66,282 shares 66,282$35.9M13.53%-3,000Timeline
BMRNBIOMARIN PHARMACEUTICAL INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 405,450 shares; 2025Q4: 524,786 shares; 2026Q1: 524,786 shares; 2026Q2: 524,786 shares; 2026Q3: 524,786 shares 524,786$31.5M11.86%0Timeline
ABTABBOTT LABORATORIESQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 5,000 shares; 2026Q2: 200,000 shares; 2026Q3: 200,000 shares 200,000$19.8M7.45%0Timeline
EXELEXELIXIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 965,866 shares; 2025Q1: 878,533 shares; 2025Q2: 493,526 shares; 2025Q3: 518,526 shares; 2025Q4: 493,526 shares; 2026Q1: 415,693 shares; 2026Q2: 370,693 shares; 2026Q3: 299,393 shares 299,393$17.5M6.59%-71,300Timeline
RAREULTRAGENYX PHARMACEUTICAL INQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 149,634 shares; 2026Q1: 390,879 shares; 2026Q2: 390,879 shares; 2026Q3: 1,140,867 shares 1,140,867$17.1M6.46%+749,988Timeline
SUPNSUPERNUS PHARMACEUTICALSQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 431,986 shares; 2025Q2: 472,376 shares; 2025Q3: 363,479 shares; 2025Q4: 313,499 shares; 2026Q1: 280,681 shares; 2026Q2: 280,681 shares; 2026Q3: 350,681 shares 350,681$15.1M5.69%+70,000Timeline
SNYSANOFI SAQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 149,196 shares; 2025Q1: 149,096 shares; 2025Q2: 148,946 shares; 2025Q3: 323,946 shares; 2025Q4: 323,946 shares; 2026Q1: 323,946 shares; 2026Q2: 323,946 shares; 2026Q3: 333,946 shares 333,946$13.8M5.19%+10,000Timeline
EMBCEMBECTA CORPQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 735,340 shares; 2026Q2: 1,135,340 shares; 2026Q3: 1,135,340 shares 1,135,340$6.43M2.42%0Timeline
ARDXARDELYX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 500,000 shares; 2026Q2: 534,523 shares; 2026Q3: 1,815,492 shares 1,815,492$6.21M2.34%+1,280,969Timeline
BNTXBIONTECH SEQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 88,663 shares; 2025Q1: 87,563 shares; 2025Q2: 73,382 shares; 2025Q3: 79,366 shares; 2025Q4: 99,523 shares; 2026Q1: 59,523 shares; 2026Q2: 59,523 shares; 2026Q3: 59,523 shares 59,523$5.85M2.2%0Timeline
VNDAVANDA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 378,762 shares; 2025Q1: 754,381 shares; 2025Q2: 1,024,883 shares; 2025Q3: 1,180,388 shares; 2025Q4: 1,180,388 shares; 2026Q1: 1,180,388 shares; 2026Q2: 1,180,388 shares; 2026Q3: 1,180,388 shares 1,180,388$5.8M2.18%0Timeline
GSKGSK PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: 272,000 shares; 2025Q2: 271,729 shares; 2025Q3: 271,729 shares; 2025Q4: 96,729 shares; 2026Q1: 96,729 shares; 2026Q2: 96,729 shares; 2026Q3: 96,729 shares 96,729$4.66M1.76%0Timeline
BIIBBIOGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: 108,923 shares; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 10,000 shares; 2025Q4: 10,000 shares; 2026Q1: 20,000 shares; 2026Q2: 20,000 shares; 2026Q3: 20,000 shares 20,000$4.52M1.7%0Timeline
INMDINMODE LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 120,942 shares; 2026Q2: 120,942 shares; 2026Q3: 120,942 shares 120,942$1.71M0.65%0Timeline
ANIPANI PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 13,000 shares 13,000$944K0.36%newTimeline
ACADACADIA PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 40,000 shares 40,000$806K0.3%newTimeline
ZTSZOETIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 10,000 shares 10,000$698K0.26%newTimeline
EOLSEVOLUS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 100,000 shares; 2025Q4: 100,000 shares; 2026Q1: 157,985 shares; 2026Q2: 157,985 shares; 2026Q3: 57,985 shares 57,985$464K0.17%-100,000Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
REGNREGENERON PHARMACEUTICALS6,000$3.74Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001609251-26-000006 base2026-11-17